BACKGROUND: Asthma is an inflammatory condition often punctuated by episodic symptomatic worsening, and accordingly, patients with asthma might have waxing and waning adherence to controller therapy. OBJECTIVE: We sought to measure changes in inhaled corticosteroid (ICS) adherence over time and to estimate the effect of this changing pattern of use on asthma exacerbations. METHODS: ICS adherence was estimated from electronic prescription and fill information for 298 participants in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity. For each patient, we calculated a moving average of ICS adherence for each day of follow-up. Asthma exacerbations were defined as the need for oral corticosteroids, an asthma-related emergency department visit, or an asthma-related hospitalization. Proportional hazard models were used to assess the relationship between ICS medication adherence and asthma exacerbations. RESULTS: Adherence to ICS medications began to increase before the first asthma exacerbation and continued afterward. Adherence was associated with a reduction in exacerbations but was only statistically significant among patients whose adherence was greater than 75% of the prescribed dose (hazard ratio, 0.61; 95% CI, 0.41-0.90) when compared with patients whose adherence was 25% or less. This pattern was largely confined to patients whose asthma was not well controlled initially. An estimated 24% of asthma exacerbations were attributable to ICS medication nonadherence. CONCLUSIONS: ICS adherence varies in the time period leading up to and after an asthma exacerbation, and nonadherence likely contributes to a large number of these exacerbations. High levels of adherence are likely required to prevent these events.
BACKGROUND: Asthma is an inflammatory condition often punctuated by episodic symptomatic worsening, and accordingly, patients with asthma might have waxing and waning adherence to controller therapy. OBJECTIVE: We sought to measure changes in inhaled corticosteroid (ICS) adherence over time and to estimate the effect of this changing pattern of use on asthma exacerbations. METHODS:ICS adherence was estimated from electronic prescription and fill information for 298 participants in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity. For each patient, we calculated a moving average of ICS adherence for each day of follow-up. Asthma exacerbations were defined as the need for oral corticosteroids, an asthma-related emergency department visit, or an asthma-related hospitalization. Proportional hazard models were used to assess the relationship between ICS medication adherence and asthma exacerbations. RESULTS: Adherence to ICS medications began to increase before the first asthma exacerbation and continued afterward. Adherence was associated with a reduction in exacerbations but was only statistically significant among patients whose adherence was greater than 75% of the prescribed dose (hazard ratio, 0.61; 95% CI, 0.41-0.90) when compared with patients whose adherence was 25% or less. This pattern was largely confined to patients whose asthma was not well controlled initially. An estimated 24% of asthma exacerbations were attributable to ICS medication nonadherence. CONCLUSIONS:ICS adherence varies in the time period leading up to and after an asthma exacerbation, and nonadherence likely contributes to a large number of these exacerbations. High levels of adherence are likely required to prevent these events.
Authors: B Bender; F S Wamboldt; S L O'Connor; C Rand; S Szefler; H Milgrom; M Z Wamboldt Journal: Ann Allergy Asthma Immunol Date: 2000-11 Impact factor: 6.347
Authors: T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; O Selroos; A Sovijärvi Journal: N Engl J Med Date: 1994-09-15 Impact factor: 91.245
Authors: T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; K Reinikainen; O Selroos Journal: N Engl J Med Date: 1991-08-08 Impact factor: 91.245
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Karen E Wells; Edward L Peterson; Brian K Ahmedani; Richard K Severson; Julie Gleason-Comstock; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2012-01-26 Impact factor: 10.793
Authors: Giselle Mosnaim; Hong Li; Molly Martin; DeJuran Richardson; Paula Jo Belice; Elizabeth Avery; Norman Ryan; Bruce Bender; Lynda Powell Journal: J Allergy Clin Immunol Pract Date: 2013-08-30
Authors: Ann Chen Wu; Melissa G Butler; Lingling Li; Vicki Fung; Elyse O Kharbanda; Emma K Larkin; William M Vollmer; Irina Miroshnik; Robert L Davis; Tracy A Lieu; Stephen B Soumerai Journal: Ann Am Thorac Soc Date: 2015-02
Authors: Mostafa El-Refai; Edward L Peterson; Karen Wells; Tanmay Swadia; Hani N Sabbah; John A Spertus; L Keoki Williams; David E Lanfear Journal: J Card Fail Date: 2013-02 Impact factor: 5.712
Authors: Albert M Levin; Yun Wang; Karen E Wells; Badri Padhukasahasram; James J Yang; Esteban G Burchard; L Keoki Williams Journal: Am J Respir Crit Care Med Date: 2014-08-01 Impact factor: 21.405
Authors: Lingling Li; William M Vollmer; Melissa G Butler; Pingsheng Wu; Elyse O Kharbanda; Ann Chen Wu Journal: Am J Epidemiol Date: 2014-01-23 Impact factor: 4.897
Authors: Jennifer A Rumpel; Brian K Ahmedani; Edward L Peterson; Karen E Wells; Mao Yang; Albert M Levin; James J Yang; Rajesh Kumar; Esteban González Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2012-10-12 Impact factor: 10.793